Mary Ogunlowo-Omobhude
Psychiatric/Mental Health · Glen Burnie, MDNPI 1508324971
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,168 of the $5,414 with a category attached, or 77.0%. 19 manufacturers reported payments, led by Neuronetics, Inc. at 32.5% of the total. Among psychiatric/mental health clinicians in MD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 178 payments — averaging $30.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neuronetics, Inc.$2K
- Teva Pharmaceuticals USA, Inc.$549
- AbbVie$529
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$333
- Lundbeck LLC$330
- Neurocrine Biosciences, Inc.$322
- plus $2K from 13 others
What the payments were for
- Travel & lodging$1,14421%
- Food & beverage$4,16877%
- Education$1012%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neuronetics, Inc. | 2 | $1,762 |
| Teva Pharmaceuticals USA, Inc. | 20 | $549 |
| AbbVie | 28 | $529 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 18 | $333 |
| Lundbeck LLC | 17 | $330 |
| Neurocrine Biosciences, Inc. | 15 | $322 |
| E.r. Squibb & Sons, L.L.C. | 12 | $317 |
| Otsuka America Pharmaceutical, Inc. | 15 | $286 |
| Alkermes, Inc. | 15 | $255 |
| Indivior Inc. | 7 | $179 |
| Supernus Pharmaceuticals, Inc. | 5 | $94 |
| Orexo US, Inc. | 5 | $92 |
| Vanda Pharmaceuticals Inc. | 5 | $84 |
| Corium, LLC | 3 | $77 |
| Sunovion Pharmaceuticals Inc. | 4 | $65 |
| Johnson & Johnson | 2 | $53 |
| Axsome Therapeutics, Inc. | 3 | $50 |
| Noven Therapeutics, LLC | 1 | $20 |
| Tempus AI, Inc | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NEUROSTAR TMS THERAPY SYSTEM$1,762
- COBENFY$119
- AUSTEDO$112
How this compares
$5,414 in reported general payments places this provider in the 95th percentile of 1,461 psychiatric/mental health providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 19 | $94,028 |
| VraylarCariprazine Hcl | 53 | $78,236 |
| Invega SustennaPaliperidone Palmitate | 11 | $25,057 |
| Aripiprazole | 56 | $1,940 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 22 | $1,783 |
| Ziprasidone Hcl | 22 | $1,605 |
| Quetiapine Fumarate | 99 | $1,100 |
| Hydroxyzine Hcl | 72 | $1,028 |
| Trazodone Hcl | 136 | $933 |
| Clozapine | 17 | $889 |
| Divalproex Sodium ErDivalproex Sodium | 30 | $880 |
| Divalproex Sodium | 41 | $789 |
| Haloperidol | 39 | $728 |
| Olanzapine | 54 | $728 |
| Benztropine Mesylate | 43 | $591 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo | $549 | $94,02819 claims |
| AbbVieVraylar | $529 | $78,23653 claims |
| Johnson & JohnsonInvega Sustenna | $53 | $25,05711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,461 psychiatric/mental health providers in Maryland.
Other psychiatric/mental health in Glen Burnie
- Ilya RozenbergGlen Burnie$572K
- Travis BairdGlen Burnie$11K
- Ololade AdekoyaGlen Burnie$6K
- Hara OyedejiOwings Mills$780K
- Michelle WilliamsColumbia$158K
- Kristin ClemensGaithersburg$36K
- Antonio HeroldHavre de Grace$23K
- Paul KlaverweidenFruitland$17K
- Margaret WebbAberdeen$16K
- Susan KrausTowson$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.